Deepika Darbari MD

PubMed

• 1 citations
  Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
  Modupe Idowu, Lucas Otieno, Bogdan Dumitriu, Clarisse L C Lobo, Swee Lay Thein
  The Lancet. Haematology. 2025-01-01
• 1 citations
  Feasibility and preliminary efficacy of the Balance Program to reduce pain-related disability in pediatric sickle cell disease.
  Megan E Connolly, Sydney Forman, Christina M Sharkey, Stephanie Merwin, Deepika S Darbari
  Pediatric Blood & Cancer. 2023-12-01
• 2 citations
  Life after sickle cell disease, is it really uhuru?
  Lydia H Pecker, Adeseye M Akinsete, C Patrick Carroll, Sophie Lanzkron, Kevin H M Kuo
  The Lancet. Haematology. 2023-12-01

Journal Articles

• Graph Theory Analysis Reveals How Sickle Cell Disease Impacts Neural Networks of Patients with More Severe Disease  
  Yvonne Datta, Deepika S Darbari, Bin He, ScienceDirect

Abstracts/Posters

• Transcranial Doppler Screening in Children with Sickle Cell Anemia Is Feasible in Central India and Reveals High Risk of Stroke
  Deepika S. Darbari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Pria...
  Deepika S. Darbari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoeti... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018